What are the deal terms?

Up to $2.35 billion: $1.65 billion upfront in cash and stock (including $1.25B via 105.8 million Telix shares and assumption of $302M of ITM net debt), plus $700 million contingent on ITM-11 hitting regulatory and sales milestones. ITM holders would own 23.7% of the combined company.

Why does Telix want ITM?

Radiopharmaceuticals depend on radioactive isotopes that are hard to make, decay fast and are in short supply. ITM is a major isotope manufacturer (actinium-225, lutetium-177, terbium-161) serving 65+ countries, so the deal secures critical supply plus a late-stage drug, ITM-11.

What is a radiopharmaceutical?

A targeted radioactive drug: a homing molecule delivers radiation directly to cancer cells while largely sparing healthy tissue. It is a fast-growing area of oncology, but constrained by the difficulty of producing the required isotopes.

Telix to Acquire ITM in Up-to-$2.35B Radiopharmaceutical Deal

The deal pairs Telix’s targeted cancer therapies with ITM’s ability to make the scarce radioactive isotopes the whole field depends on — a bid to own more of a fast-growing, supply-constrained business.

Telix Pharmaceuticals is acquiring ITM in a deal worth up to $2.35 billion, a move designed to create what Telix calls a “radiopharmaceutical powerhouse” — and to lock down the scarce raw material that this booming corner of cancer medicine runs on.

The deal

Telix will pay $1.65 billion upfront in cash and stock — including $1.25 billion via 105.8 million Telix shares (priced at $11.841 each) plus assumption of $302 million of ITM net debt — with an additional $700 million contingent on ITM’s lead drug hitting regulatory and sales milestones. When it closes (expected by end of 2026, pending shareholder and regulatory approvals), ITM shareholders will own 23.7% of the combined company and existing Telix holders 76.3%.

What radiopharmaceuticals are

Radiopharmaceuticals are targeted radioactive drugs: a homing molecule seeks out cancer cells and delivers a payload of radiation directly to the tumor, sparing healthy tissue. It’s one of oncology’s hottest areas. But there’s a catch that makes this deal strategic: the therapies depend on radioactive isotopes that are hard to produce, decay quickly, and are chronically in short supply.

Why ITM is the prize

That’s exactly what ITM brings. The company is a major manufacturer of medical radioisotopes — including actinium-225, lutetium-177 and terbium-161 — supplying more than 65 countries. It’s also a real business, not just a supplier: $273 million in 2025 revenue, growing at a 40% compound annual rate since 2021. And it has a late-stage drug of its own, ITM-11 (lutetium-177 edotreotide), which has completed Phase III trials for gastroenteropancreatic neuroendocrine tumors. So Telix gets both the isotope supply and a near-market therapy.

The strategic logic

In radiopharmaceuticals, whoever controls isotope production controls the bottleneck. By owning manufacturing rather than depending on outside suppliers, Telix insulates itself from the shortages that can stall the entire field, and positions itself to scale as demand grows. CEO Christian Behrenbruch framed it as putting Telix “at the forefront of industry consolidation” as the sector matures — a telling phrase, since a wave of dealmaking is reshaping radiopharma.

Why it matters — and the caveat

Vertical integration — owning the drug and its critical supply — is a powerful position in a market projected to grow strongly, and it echoes similar moves across the sector (recent facility buildouts and mergers). For patients, more resilient isotope supply could mean fewer treatment delays. The caveats are the usual ones for large M&A: the deal must clear shareholder and regulatory approval, and part of the value ($700M) hinges on ITM-11’s commercial success, which isn’t guaranteed. Business news, not investment advice.

This article is for general information only and is not medical advice. Consult a qualified healthcare professional for any medical decisions.

Telix Bets Up to $2.35B on ITM to Build a Radiopharmaceutical Powerhouse